After trimming its cell therapy pipeline last year, the group is now out entirely.

Conference activity picks up, with the big one – ASCO – at the end of the month.

The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.

The Japanese group licenses sapablursen from Ionis for $280m.

Rusfertide, the subject of a 2024 tie-up, scores in phase 3.

Rusfertide’s big readout will now not come until 2025.